These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 26602277)
1. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277 [TBL] [Abstract][Full Text] [Related]
2. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors. Cox CD; Hostetler ED; Flores BA; Evelhoch JL; Fan H; Gantert L; Holahan M; Eng W; Joshi A; McGaughey G; Meng X; Purcell M; Raheem IT; Riffel K; Yan Y; Renger JJ; Smith SM; Coleman PJ Bioorg Med Chem Lett; 2015 Nov; 25(21):4893-4898. PubMed ID: 26077491 [TBL] [Abstract][Full Text] [Related]
3. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116 [TBL] [Abstract][Full Text] [Related]
4. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia. Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746 [TBL] [Abstract][Full Text] [Related]
6. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia. Bartolomé-Nebreda JM; Alonso de Diego SA; Artola M; Delgado F; Delgado Ó; Martín-Martín ML; Martínez-Viturro CM; Pena MÁ; Tong HM; Van Gool M; Alonso JM; Fontana A; Macdonald GJ; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S J Med Chem; 2015 Jan; 58(2):978-93. PubMed ID: 25495129 [TBL] [Abstract][Full Text] [Related]
8. Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors. Varnes JG; Geschwindner S; Holmquist CR; Forst J; Wang X; Dekker N; Scott CW; Tian G; Wood MW; Albert JS Bioorg Med Chem Lett; 2016 Jan; 26(1):197-202. PubMed ID: 26597534 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Characterization of the Phosphodiesterase 10A PET Tracer [(11)C]MK-8193. Hostetler ED; Fan H; Joshi AD; Zeng Z; Eng W; Gantert L; Holahan M; Meng X; Miller P; O'Malley S; Purcell M; Riffel K; Salinas C; Williams M; Ma B; Buist N; Smith SM; Coleman PJ; Cox CD; Flores BA; Raheem IT; Cook JJ; Evelhoch JL Mol Imaging Biol; 2016 Aug; 18(4):579-87. PubMed ID: 26596571 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety. Koizumi Y; Tanaka Y; Matsumura T; Kadoh Y; Miyoshi H; Hongu M; Takedomi K; Kotera J; Sasaki T; Taniguchi H; Watanabe Y; Takakuwa M; Kojima K; Baba N; Nakamura I; Kawanishi E Bioorg Med Chem; 2019 Aug; 27(15):3440-3450. PubMed ID: 31235264 [TBL] [Abstract][Full Text] [Related]
11. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux. Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228 [TBL] [Abstract][Full Text] [Related]
12. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197 [TBL] [Abstract][Full Text] [Related]
13. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Layton ME; Kern JC; Hartingh TJ; Shipe WD; Raheem I; Kandebo M; Hayes RP; Huszar S; Eddins D; Ma B; Fuerst J; Wollenberg GK; Li J; Fritzen J; McGaughey GB; Uslaner JM; Smith SM; Coleman PJ; Cox CD J Med Chem; 2023 Jan; 66(2):1157-1171. PubMed ID: 36624931 [TBL] [Abstract][Full Text] [Related]
14. Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors. Geneste H; Drescher K; Jakob C; Laplanche L; Ochse M; Torrent M Bioorg Med Chem Lett; 2019 Feb; 29(3):406-412. PubMed ID: 30587449 [TBL] [Abstract][Full Text] [Related]
15. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043 [TBL] [Abstract][Full Text] [Related]
16. Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition. Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902 [TBL] [Abstract][Full Text] [Related]
18. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability. Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154 [TBL] [Abstract][Full Text] [Related]
19. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors. Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358 [TBL] [Abstract][Full Text] [Related]
20. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies. Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]